title: Development and testing of an inactivated feline leukemia virus vaccine.
abstract: We assessed an inactivated whole virus feline leukemia virus (FeLV) vaccine developed from a molecularly cloned feline leukemia virus isolate (FeLV-61E-A) for its ability to protect cats against homologous and heterologous virulent virus challenge. The fractions of cats that resisted the induction of persistent viremia after FeLV challenge were the following: (1) FeLV-61E-A vaccine, 95%; (2) adjuvant controls, 26%; and (3) established commercial control FeLV vaccine, 35%. The pre-challenge mean neutralizing antibody titers for each group were (1) FeLV-61E-A vaccine, 1:43; (2) adjuvant controls, <1:8; and (3) established commercial control FeLV vaccine: 1:12. The commercial version of the prototype FeLV-61E-A vaccine (Fel-O-Vax, Fort Dodge Laboratories, Fort Dodge, IA) was developed through use of a proprietary adjuvant and a stable high antigen production cell lines. The efficacy and duration of immunity produced by Fel-O-Vax was studied alone and in multivalent combination with other feline virus vaccines in seven subsequent efficacy trials conducted in over 150 immunized cats. The overall FeLV-resistant fraction in these trials was 87% in vaccinated cats versus 8% in adjuvant controls. The duration of protective immunity induced by the multivalent Fel-O-Vax-LvK IV at 1 year postvaccination was 100% in challenged vaccinees versus 0% in challenged controls. The results of these studies show that an inactivated FeLV vaccine prepared from a molecularly cloned subgroup A FeLV can produce high level protective immunity against FeLV infection. This immunity is durable for at least 1 year without intervening booster immunization or virus exposure.
authors.affiliation: Department of Pathology, Colorado State University, Fort Collins 80523, USA.
authors.forename: E A
authors.initials: EA
authors.lastname: Hoover
authors.forename: J I
authors.initials: JI
authors.lastname: Mullins
authors.forename: H J
authors.initials: HJ
authors.lastname: Chu
authors.forename: T L
authors.initials: TL
authors.lastname: Wasmoen
mesh_terms: D000818:Animals; D002415:Cats; D003001:Cloning, Molecular; D005256:Leukemia Virus, Feline / Q000276:immunology*; D016582:Leukemia, Feline / Q000517:prevention & control*; D015164:Vaccines, Inactivated / Q000008:administration & dosage / Q000096:biosynthesis / Q000276:immunology; D014765:Viral Vaccines / Q000008:administration & dosage / Q000096:biosynthesis / Q000276:immunology*
chemical_list: D015164:Vaccines, Inactivated; D014765:Viral Vaccines